M. Schlemmer

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA · 2012 · 955 citations

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne et al. · European Journal of Cancer · 2006 · 893 citations

Oncology, Gastrointestinal Oncology, Medicine +10

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg

John Zalcberg, Jaap Verweij, Paolo G. Casali et al. · European Journal of Cancer · 2005 · 373 citations

Daily Imatinib Dose, Gastrointestinal Oncology, Medicine +8

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

M. van Glabbeke, Jaap Verweij, Paolo G. Casali et al. · Journal of Clinical Oncology · 2005 · 279 citations

Imatinib Dose, European Organisation, Different Prognostic Factors +13

Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group

M. Schlemmer, Peter Reichardt, Jaap Verweij et al. · European Journal of Cancer · 2008 · 233 citations

Surgical Oncology, Tumoral Pathology, Bone Sarcoma Group +8